---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044829"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:26:59.967832+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M

## Summary
- Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.
- Adjusted EBITDA improved to $0.8M from $0.3M in prior-year quarter.
- Appointed Keith Myers (former LHC Group CEO) to the board; invested $5.0M in ChemoMouthpiece for 6.64% stake and exclusive U.S. distribution.
- Products now sold in over 1,200 facilities; contracted in 4,000+ hospitals; distributor network expanded to 300+.

## SEC filing metadata
- accession: 0001493152-24-044829
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/0001493152-24-044829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315224044829/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044829
- JSON: https://secwatch.observer/filing/0001493152-24-044829.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.